drugset / Trial / NCT06088433
Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease
RandomizedParallel-groupSingle-blindTreatment
Summary
The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB) therapy.
Timeline
- Start
- 2023-11-15
- Primary completion
- 2024-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 60 mg | — |